Crossbow Therapeutics
Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does Crossbow Therapeutics do?
Crossbow Therapeutics is a biotechnology company focused on developing novel T-cell receptor (TCR)-mimetic antibody therapies for the treatment of cancer. Their approach aims to leverage the specificity of T-cell receptors to target cancer cells with high precision. The company recently announced a $77 million Series B financing round to advance its pipeline.
How much funding has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised a total of $157M in funding. The most recent round on record is Series B.
Where is Crossbow Therapeutics headquartered?
Crossbow Therapeutics is headquartered in Cambridge, United States.
When was Crossbow Therapeutics founded?
Crossbow Therapeutics was founded in 2021.
What industry does Crossbow Therapeutics operate in?
Crossbow Therapeutics operates in Biotechnology, Pharmaceuticals, Cancer, Immunotherapy, Oncology.
How many employees does Crossbow Therapeutics have?
Crossbow Therapeutics has approximately 40 people on record.